ATE429217T1 - Nateglinid enthaltende hydrophile arzneimittelpräparate - Google Patents

Nateglinid enthaltende hydrophile arzneimittelpräparate

Info

Publication number: ATE429217T1
Authority: AT; Austria
Prior art keywords: preparation; nateglinide; hydrophilic; preparations containing; medicinal preparations
Prior art date: 2000-10-24

Application number

AT01976818T

Other languages

English (en)

Inventor

Nobutaka Ninomiya

Chisato Makino

Akira Yabuki

Original Assignee

Ajinomoto Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-24

Filing date

2001-10-23

Publication date

2009-05-15

2001-10-23 Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE429217T1 publication Critical patent/ATE429217T1/de

Links

238000002360 preparation method Methods 0.000 title abstract 4
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title abstract 3
229960000698 nateglinide Drugs 0.000 title abstract 3
239000013078 crystal Substances 0.000 abstract 1
238000004090 dissolution Methods 0.000 abstract 1
229920001477 hydrophilic polymer Polymers 0.000 abstract 1
239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
235000000346 sugar Nutrition 0.000 abstract 1
150000005846 sugar alcohols Chemical class 0.000 abstract 1
150000008163 sugars Chemical class 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT01976818T 2000-10-24 2001-10-23 Nateglinid enthaltende hydrophile arzneimittelpräparate ATE429217T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000324374		2000-10-24
PCT/JP2001/009292 WO2002040010A1 (fr)	2000-10-24	2001-10-23	Preparations de medicament contenant du nateglinide

Publications (1)

Publication Number	Publication Date
ATE429217T1 true ATE429217T1 (de)	2009-05-15

Family

ID=18801919

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01976818T ATE429217T1 (de)	2000-10-24	2001-10-23	Nateglinid enthaltende hydrophile arzneimittelpräparate

Country Status (19)

Country	Link
US (1)	US20040029968A1 (de)
EP (1)	EP1334721B1 (de)
JP (3)	JPWO2002040010A1 (de)
KR (1)	KR100829410B1 (de)
CN (1)	CN100531730C (de)
AT (1)	ATE429217T1 (de)
AU (1)	AU2001296000A1 (de)
BR (1)	BR0114897A (de)
CA (1)	CA2426764C (de)
CY (1)	CY1110320T1 (de)
DE (1)	DE60138476D1 (de)
DK (1)	DK1334721T3 (de)
ES (1)	ES2321911T3 (de)
MX (1)	MXPA03003686A (de)
PT (1)	PT1334721E (de)
RU (1)	RU2283104C2 (de)
SI (1)	SI1334721T1 (de)
TW (1)	TWI289461B (de)
WO (1)	WO2002040010A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2248159T3 (es) *	1999-12-28	2006-03-16	Ajinomoto Co., Inc.	Preparaciones orales para diabetes.
AU2001295999A1 (en) *	2000-10-24	2002-05-06	Ajinomoto Co., Inc.	Nateglinide-containing preparations
US6861553B2 (en)	2002-07-03	2005-03-01	Teva Pharmaceuticals Industries Ltd.	Process for preparing nateglinide and intermediates thereof
US7358390B2 (en)	2002-07-18	2008-04-15	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7420084B2 (en)	2002-07-18	2008-09-02	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7148376B2 (en)	2002-07-18	2006-12-12	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7534913B2 (en)	2002-07-18	2009-05-19	Teva Pharmaceutica Industries Ltd.	Crystalline form of nateglinide
WO2005013964A1 (ja) *	2003-08-08	2005-02-17	Ajinomoto Co., Inc.	ナテグリニド含有製剤
WO2005020979A1 (en) *	2003-09-03	2005-03-10	Ranbaxy Laboratories Limited	A process for the preparation of pharmaceutical compositions of nateglinide
US20070219250A1 (en) *	2003-11-28	2007-09-20	Romi Singh	Pharmaceutical Compositions of Nateglinide
WO2005092319A1 (en) *	2004-03-29	2005-10-06	Ranbaxy Laboratories Limited	Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2005094812A1 (ja) *	2004-04-01	2005-10-13	Ajinomoto Co., Inc.	ナテグリニド含有製剤
WO2009038770A2 (en) *	2007-09-20	2009-03-26	University Of Massachusetts Cvip	Detoxified recombinant botulinum neurotoxin
WO2013066278A1 (en) *	2011-11-03	2013-05-10	Mahmut Bilgic	A process for production of pharmaceutical formulations comprising nateglinide
EP2809316A1 (de) *	2012-01-31	2014-12-10	Mahmut Bilgic	Synergistische kombination aus einem meglitinidderivat und liponsäure
CA3176569A1 (en) *	2020-03-27	2021-09-30	Pfizer Inc.	Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH066532B2 (ja) *	1983-09-29	1994-01-26	日産化学工業株式会社	親水性コロイドにより変性したワックス性微粉末
JPS6354321A (ja) *	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
US5474989A (en) *	1988-11-11	1995-12-12	Kurita Water Industries, Ltd.	Drug composition
DK0526171T3 (da) *	1991-07-30	1997-08-25	Ajinomoto Kk	Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf
US5463116A (en) *	1991-07-30	1995-10-31	Ajinomoto Co., Inc.	Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JPH0696517B2 (ja) *	1993-03-17	1994-11-30	日産化学工業株式会社	変性したワックス性微粉末で被覆された薬剤及びその製造法
JP2994956B2 (ja)	1994-05-31	1999-12-27	信越化学工業株式会社	低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
KR100343062B1 (ko) *	1996-11-15	2002-07-02	에가시라 구니오	정제 조성물
CA2216215A1 (en) *	1997-04-05	1998-10-05	Isa Odidi	Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP3591801B2 (ja) *	1997-06-19	2004-11-24	田辺製薬株式会社	口腔内速崩壊性製剤の製法
JP2000178183A (ja) *	1998-12-17	2000-06-27	Lion Corp	固形製剤及びその製造方法
JP2000290171A (ja) *	1999-04-06	2000-10-17	Eisai Co Ltd	崩壊のはやい錠剤又はその製造方法
ES2248159T3 (es) *	1999-12-28	2006-03-16	Ajinomoto Co., Inc.	Preparaciones orales para diabetes.
EP1283054A4 (de) *	2000-03-17	2006-04-12	Ajinomoto Kk	Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
ATE373635T1 (de) *	2000-10-18	2007-10-15	Ajinomoto Kk	Verfahren zur herstellung von acylphenylalaninen
WO2002032854A1 (en) *	2000-10-18	2002-04-25	Ajinomoto Co.,Inc.	Process for producing nateglinide crystal
BR0114846A (pt) *	2000-10-24	2004-02-25	Ajinomoto Kk	Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h
AU2001295999A1 (en) *	2000-10-24	2002-05-06	Ajinomoto Co., Inc.	Nateglinide-containing preparations
US6830759B2 (en) *	2002-06-28	2004-12-14	Ajinomoto Co., Inc.	Antidiabetic preparation for oral administration

2001
- 2001-10-23 PT PT01976818T patent/PT1334721E/pt unknown
- 2001-10-23 CN CNB018212182A patent/CN100531730C/zh not_active Expired - Fee Related
- 2001-10-23 ES ES01976818T patent/ES2321911T3/es not_active Expired - Lifetime
- 2001-10-23 CA CA2426764A patent/CA2426764C/en not_active Expired - Fee Related
- 2001-10-23 MX MXPA03003686A patent/MXPA03003686A/es active IP Right Grant
- 2001-10-23 DE DE60138476T patent/DE60138476D1/de not_active Expired - Lifetime
- 2001-10-23 TW TW090126184A patent/TWI289461B/zh not_active IP Right Cessation
- 2001-10-23 BR BR0114897-4A patent/BR0114897A/pt not_active IP Right Cessation
- 2001-10-23 EP EP01976818A patent/EP1334721B1/de not_active Expired - Lifetime
- 2001-10-23 AT AT01976818T patent/ATE429217T1/de active
- 2001-10-23 WO PCT/JP2001/009292 patent/WO2002040010A1/ja not_active Ceased
- 2001-10-23 KR KR1020037005635A patent/KR100829410B1/ko not_active Expired - Fee Related
- 2001-10-23 SI SI200130912T patent/SI1334721T1/sl unknown
- 2001-10-23 DK DK01976818T patent/DK1334721T3/da active
- 2001-10-23 AU AU2001296000A patent/AU2001296000A1/en not_active Abandoned
- 2001-10-23 JP JP2002542384A patent/JPWO2002040010A1/ja active Pending
- 2001-10-23 RU RU2003111949/15A patent/RU2283104C2/ru not_active IP Right Cessation
2003
- 2003-04-23 US US10/420,886 patent/US20040029968A1/en not_active Abandoned
2009
- 2009-06-11 CY CY20091100623T patent/CY1110320T1/el unknown
2010
- 2010-02-04 JP JP2010023025A patent/JP5278708B2/ja not_active Expired - Fee Related
2013
- 2013-01-11 JP JP2013003337A patent/JP5673972B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2013064018A (ja)	2013-04-11
SI1334721T1 (sl)	2009-08-31
CN1482904A (zh)	2004-03-17
KR20030042028A (ko)	2003-05-27
AU2001296000A1 (en)	2002-05-27
BR0114897A (pt)	2003-08-12
EP1334721A1 (de)	2003-08-13
ES2321911T3 (es)	2009-06-15
RU2283104C2 (ru)	2006-09-10
CY1110320T1 (el)	2015-01-14
EP1334721A4 (de)	2005-11-02
DE60138476D1 (de)	2009-06-04
DK1334721T3 (da)	2009-07-06
PT1334721E (pt)	2009-06-01
KR100829410B1 (ko)	2008-05-15
CA2426764C (en)	2010-04-20
JP5278708B2 (ja)	2013-09-04
CN100531730C (zh)	2009-08-26
US20040029968A1 (en)	2004-02-12
JP5673972B2 (ja)	2015-02-18
EP1334721B1 (de)	2009-04-22
JPWO2002040010A1 (ja)	2004-06-03
TWI289461B (en)	2007-11-11
JP2010095551A (ja)	2010-04-30
CA2426764A1 (en)	2003-04-23
MXPA03003686A (es)	2004-01-26
WO2002040010A1 (fr)	2002-05-23

Legal Events

Date

Code

Title

Description

2009-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1334721

Country of ref document: EP

Publication	Publication Date	Title
CY1110320T1 (el)	2015-01-14	Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)
BR9908121A (pt)	2000-10-24	Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
ES2354244T3 (es)	2011-03-11	Proceso de preparación de formas de administración rápidamente disgregables para la liberación de principios activos en la cavidad bucal o en cavidades corporales.
AR029716A1 (es)	2003-07-10	Productos dermatologicos en forma de hoja
JP4387356B2 (ja)	2009-12-16	超音波導入スキンケアデバイス
CA2416869A1 (en)	2002-01-31	Vaccines
ES2075249T3 (es)	1995-10-01	Dispositivo adhesivo para la administracion transdermica de un agente activo.
DE68922894D1 (de)	1995-07-06	Pharmazeutische Ionenaustauscherharzzusammensetzung.
RU2000123567A (ru)	2002-11-10	Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
KR20040002391A (ko)	2004-01-07	경구투여제 및 경구투여제 유지체
DE69414840D1 (de)	1999-01-07	Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
IT1246188B (it)	1994-11-16	Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
KR101489524B1 (ko)	2015-02-03	발포성 보습 조성물
ES2193726T3 (es)	2003-11-01	Formulaciones de aerosol medicinales.
CA2320039A1 (en)	1999-08-19	Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
WO2002045684A3 (en)	2003-03-13	Rapidly dispersing pharmaceutical composition comprising effervescent agents
EP0350701A3 (de)	1990-09-19	Arzneimittel zur oralen Verabreichung mit analgetischer und antiinflammatorischer Wirkung, die einen ausgezeichneten Geschmack besitzen und frei von irritierenden Effekten auf die Schleimhäute sind
RU2003111949A (ru)	2004-08-27	Гидрофильный фармацевтический препарат, содержащий натеглинид
CA2617659A1 (en)	2007-02-08	Use of hydroxybenzoic acid esters and analogues for the manufacture of a medicament for the prevention and treatment of virus infection
DE59509928D1 (de)	2002-01-24	Antihyperglykämisch wirksame Arzneimittel
CO4700033A1 (es)	1998-12-29	Preparados de liberacion controlada a base de una sal pota- sica alcalinizante
ATE262350T1 (de)	2004-04-15	Flüssige pharmazeutische zusammensetzung zur oralen verabreichung bitterschmeckender hydrolyseempfindlicher aktivstoffe
JP2003081840A (ja)	2003-03-19	清涼化方法、清涼化剤および外用組成物
ES2092559T3 (es)	1996-12-01	Formulacion farmaceutica que contiene penciclovir.
WO2004037226B1 (en)	2004-09-10	Pharmaceutical compositions containing venlafaxine